We have 3 of 59 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
HF in cardio-oncology patients exhibits a distinct metabolomic phenotype that differs from classical HF and reflects key pathogenetic mechanisms of myocardial injury, enabling detection of subclinical cardiotoxicity.
Endothelin-1 is a promising early diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoma patients with low and intermediate CVT-risk receiving anthracycline-based chemotherapy and may facilitate early risk reclassification and optimization of cardio-oncology surveillance...
In patients with low and moderate baseline CV risk, a statistically significant deterioration in lipid profile was observed during chemotherapy, which is consistent with the development of subclinical endothelial dysfunction and early vascular toxicity, despite the absence of overt clinical manifestations of vasculotox...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
